Skip to content

NCI K99 Clinical Trial Required Guide

Updated 8 official sources

Quick Answer: PAR-25-313 is the NCI K99/R00 Pathway to Independence Award for candidates proposing independent clinical trials.

Full answer and how we checked it

It is clinical trial required, can support up to 5 total years, and is for postdoctoral researchers who need at least 12 months of mentored K99 work before moving to an independent R00 phase. It's also closing out: NIH's NOT-OD-26-098 (opens in a new tab) ends clinical-trial-required K NOFOs, with current K NOFOs expiring by July 13, 2027.

Who this is for: Cancer postdocs, physician-scientists, clinical trialists, mentors, department chairs, research administrators, and sponsored-research offices deciding whether the clinical-trial-required NCI K99/R00 is the right route.

Data note: This guide uses NIH PAR-25-313, NCI K99/R00 program pages and FAQ, Grants.gov listing 358202, and Grantsights award-data signals checked on May 19, 2026. Status, due dates, and NIH RePORTER awards were rechecked on October 9, 2026.

Source review by Grantsights, June 3, 2026: We rechecked NIH PAR-25-313, NCI K99/R00 FAQ material, NIH Pathway to Independence guidance, Grants.gov listing 358202, NIH clinical-trial definitions, and Grantsights program records. Where official sources stop: PAR-25-313 is the NCI clinical-trial-required K99/R00 lane, with a 6-year postdoctoral research experience screen and a mentored K99 phase that normally does not extend beyond 2 years.

In this guide

Quick Facts

Agency
HHS
Deadline
Oct 14, 2027
Status
Open

Assistance Listing 93.398: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.398, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
2,179
Avg Award (whole listing)
$1,021,124
Median Award (whole listing)
$344,088
Total Funding (FY2024, whole listing)
$216.8M
YoY Funding Trend
+2%

Data last verified: May 19, 2026

According to NIH in PAR-25-313 (opens in a new tab), this NCI K99/R00 route is clinical trial required. It only accepts applications proposing independent clinical trials. Candidates not planning an independent clinical trial should compare the companion clinical-trial-not-allowed route.

The decision question is whether the candidate is still eligible as a mentored postdoctoral researcher and whether the proposed clinical trial is truly independent enough for this route.

Use this guide with the live NCI K99/R00 clinical trial required program record. Then compare NCI K99 Clinical Trial Not Allowed guide, NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, NCI R25 Courses guide, and the Grantsights grant database.

7 PAR-25-313 Eligibility Stop Checks

Stop checkStrong K99/R00 signalRed flag
Candidate stageMentored postdoc, not independentFaculty or equivalent independence
ExperienceNo more than 6 years postdoctoral research trainingOver limit
Trial statusIndependent clinical trial is proposedNo independent trial
Mentored phaseAt least 12 months of real training needCandidate is already ready
Cancer fitNCI mission is centralWeak cancer relevance
R00 transitionTenure-track or equivalent plan is credibleNo independence path
Mentor teamTrial, career, and cancer mentors are strongMentor roles are vague

K99 applications can weaken when the candidate tries to look too independent. This award needs independence potential plus a real mentored-development need.

5 Source Facts Applicants Should Know

Start the application screen with these 5 source facts. According to NIH in PAR-25-313 (opens in a new tab), the funding number is PAR-25-313, the activity code is K99/R00, clinical trials are required, and the total project period may not exceed 5 years. NIH says NCI will contribute up to $100,000 per year toward the K99 candidate salary.

According to the NCI K99/R00 FAQ (opens in a new tab), postdoctoral candidates must have no more than 6 years of postdoctoral research training at the time of initial application or resubmission. According to USAspending.gov (opens in a new tab) data, assistance listing 93.398 had about $216.8M in FY2024 obligations across 2,179 awards active that year.

FactSource-backed read
Funding numberPAR-25-313
MechanismK99/R00 career transition award
Clinical trial statusRequired
Project periodUp to 5 years
Remaining due datesOctober 14, 2026; February 17, 2027; June 15, 2027
ExpirationNOFO lists October 15, 2027, but NOT-OD-26-098 expires current K NOFOs by July 13, 2027

What NCI Doesn't Tell You

Within 21 days, answer 4 practical questions. First, the candidate cannot be too independent. A non-mentored research position or tenure-track equivalent can block the award.

Second, the clinical trial needs ownership. For example, a postdoc proposing a pilot behavioral intervention trial should show how they'll organize, manage, and implement it, not only assist on a mentor's trial. The NOFO also accepts a clinical trial feasibility study or a separate ancillary study to an existing trial, as long as the candidate leads it.

Third, the mentored phase must be credible. Don't apply if the candidate cannot explain why at least 12 months of mentored training is needed before independence.

Fourth, the R00 phase must look like a real independent research program. The job plan, startup, protected time, and institution fit matter.

6 Evidence Assets That Make This K99/R00 Stronger

Within 21 days, build 6 evidence assets. Asset 1 is the eligibility memo: degree, postdoctoral timeline, independence status, prior grants, and institutional position.

Asset 2 is the independent clinical trial summary. Include objective, population, intervention, outcome, safety, data management, and candidate role.

Asset 3 is the mentored-development plan. State the training gaps, mentors, milestones, coursework if any, and how training connects to the trial and R00 plan.

Asset 4 is the R00 research program one-pager. It should look like a future faculty research program, not a continuation of the mentor's project.

Asset 5 is the mentor and environment table. Include cancer expertise, clinical-trial expertise, statistics, regulatory support, participant access, and career sponsorship.

Asset 6 is the route comparison. Compare PAR-25-313 with PAR-25-135, K awards, R21, and early R01 paths. Leave the parent K99/R00 off the list for cancer science: NCI stopped accepting parent applications after December 31, 2024.

5 Route Choices Before Drafting

Within 21 days, compare the NCI routes and the alternatives below.

RouteBetter first read when...Why
PAR-25-313Candidate proposes independent clinical trialRoute fits
PAR-25-135No independent clinical trial is proposedCompanion NCI route fits
Parent K99/R00Not an NCI routeNCI left PA-24-193, PA-24-194 and PA-24-195 after December 31, 2024 (NOT-CA-25-021 (opens in a new tab)); NCI K99 applications go only to PAR-25-135 or PAR-25-313, per NCI's K99 page (opens in a new tab)
K08/K23Clinician-scientist development needs differOther K route may fit
R21/R01Candidate is already independentCareer award may not fit

The strongest application can explain why K99/R00 is the right bridge now.

6 Bad-Fit Signals

First, the candidate has more than 6 years of related postdoctoral training. Second, the candidate is already independent. Third, no independent clinical trial is proposed.

Fourth, the trial is a mentor's study with the candidate in a helper role. Fifth, the cancer relevance is weak. Sixth, the R00 plan does not show a faculty-level research program.

Run these checks early, because the 6-year clock and the July 2027 cutoff both limit how many tries a candidate gets.

21-Day K99/R00 Readiness Plan

Days 1 through 3 should confirm source status, deadline, trial-required status, candidate eligibility, and postdoc timeline. Days 4 through 7 should write the independent clinical-trial summary.

Days 8 through 12 should build the training plan and mentor table. Days 13 through 16 should write the R00 independence plan. Days 17 through 21 should compare PAR-25-313, PAR-25-135, K08/K23, and R21/R01 routes.

What NIH's 2026 K Award Changes Mean for This Route

NOT-OD-26-098 (opens in a new tab), released August 12, 2026, rewrites the K program in 3 ways that hit PAR-25-313 directly:

  1. No more trial-required K awards. NIH says it "will no longer support" independent clinical trial required K NOFOs. K funds can't pay for a clinical trial, feasibility study, or ancillary study, and K awardees who want to lead a trial as PI must find separate funding for it.
  2. K99 becomes KT1/R00. The K99 and K22 fold into a new KT1/R00 "Career Transition to Research Independence Award" parent NOFO for due dates on or after October 12, 2027.
  3. No DMS plan. K applications no longer need a Data Management and Sharing Plan. NOT-OD-26-120 (opens in a new tab) (October 5, 2026) made that effective immediately, including for pending applications.

So PAR-25-313 has at most 3 due dates left: October 14, 2026, February 17, 2027, and June 15, 2027. A candidate whose trial isn't ready for one of those should plan around the KT1/R00, with the trial funded from another source and K time spent on training and mentored research.

Budget, Effort, and Eligibility Details in PAR-25-313

The NOFO's numbers are specific, and several catch candidates late:

ItemWhat PAR-25-313 says
K99 salaryNCI pays up to $100,000 per year toward candidate salary
K99 research costsUp to $30,000 per year, justified by career stage
K99 indirect costs8% of modified total direct costs
K99 lengthUp to 2 years of mentored support
R00 phaseUp to 3 years, capped at $249,000 total cost per year, at the institution's indirect rate
R00 effortAt least 75% (9 person-months) on research
CitizenshipNone required; visa must cover the K99 phase
Foreign organizationsNot eligible; foreign subawards make an application noncompliant
Applications per institutionMore than one allowed if each is from a different candidate and scientifically distinct

Three eligibility edge cases come straight from the notice. Candidates titled research assistant professor or assistant professor are treated as independent and can't apply. Leave of generally less than 12 months and clinical training with no research involvement don't count toward the 6-year limit. And anyone who's been an independent PI on an NIH R01, R03, R21, or K award, or on other peer-reviewed grants over $100,000 direct costs per year, is out.

What Funded PAR-25-313 Projects Look Like

According to NIH RePORTER (opens in a new tab) records pulled October 9, 2026, NCI had made 4 K99 awards under PAR-25-313, all in FY2026:

AwardInstitutionTrial topicFY2026 award
1K99CA308896-01AdventHealth OrlandoNutrition and proteomics for chemotherapy-induced peripheral neuropathy$176,256
1K99CA300506-01A1University of VirginiaFaith-based intervention to promote rural physical activity$115,420
1K99CA308581-01University of RochesterExercise and nutrition intervention for cancer-related fatigue$133,510
1K99CA315571-01Yale UniversityOral microbiome and inflammation biomarkers of cancer risk$154,705

Grantsights checked those records against the NOFO's budget rules. For example, AdventHealth received $176,256 for a first K99 year on a project pairing nutrition and proteomics to address chemotherapy-induced peripheral neuropathy. Three of the 4 are behavioral, exercise, or nutrition interventions, the kind of trial a postdoc can realistically lead with a modest budget. One award (the University of Virginia project) was funded on resubmission. A first-year K99 total near $115,000 to $176,000 fits the NOFO's math: up to $100,000 salary, up to $30,000 research costs, plus fringe and 8% indirects.

5 Final Research Checks Before Submission

Within 21 days, finish 5 final research checks. Check 1 is the candidate clock. The postdoctoral time limit is not a detail to check at the end.

Check 2 is independence status. A candidate can look attractive on paper and still be too independent for this route. The internal memo should check title, appointment, prior awards, PI authority, institutional commitments, and whether the person already controls an independent research program.

Check 3 is trial ownership. PAR-25-313 requires an independent clinical trial, so the application has to define the candidate's role in design, conduct, management, safety oversight, data analysis, and reporting. Helping on a mentor's trial isn't enough.

Check 4 is the mentored phase. K99/R00 applications can fail when the candidate tries to sound fully ready, and the NOFO says candidates must justify the need for the K99 phase. The application needs a serious training plan with gaps, mentors, milestones, and a reason at least 12 months of mentored work matters.

Check 5 is companion-route comparison. You're ready when the candidate can explain why PAR-25-313 beats the clinical-trial-not-allowed NCI K99/R00 (PAR-25-135), K08, K23, R21, or early R01 path. The parent K99/R00 isn't an option for an NCI application.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 2,179 Assistance Listing records | Avg: $1.0M

REAL DATA
1

Baylor College of Medicine

TX

$42.8M
2

Regents of the University of California, San Francisco, the

CA

$39.3M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Frequently Asked Questions

What does PAR-25-313 fund?

It supports NCI K99/R00 career transition awards for postdoctoral researchers proposing independent clinical trials.

Are clinical trials required?

Yes. PAR-25-313 only accepts applications that propose independent clinical trials.

What is the maximum project period?

NIH says the total project period may not exceed 5 years.

What postdoctoral experience limit applies?

Candidates must have no more than 6 years of related postdoctoral research training at initial application or resubmission.

Who should skip this route?

Skip it if the candidate is already independent, lacks an independent clinical trial, or should use the companion clinical-trial-not-allowed route.

Will PAR-25-313 stay open?

Not for long. NIH notice NOT-OD-26-098 (August 12, 2026) says NIH will no longer support independent clinical trial required K NOFOs and will expire current K NOFOs by July 13, 2027. The remaining listed due dates are October 14, 2026, February 17, 2027, and June 15, 2027.

Last updated October 13, 2026. Corrected October 13, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.